Reduced levels of pulmonary surfactant in COVID-19 ARDS
- PMID: 35260704
- PMCID: PMC8904856
- DOI: 10.1038/s41598-022-07944-4
Reduced levels of pulmonary surfactant in COVID-19 ARDS
Abstract
To provide novel data on surfactant levels in adult COVID-19 patients, we collected bronchoalveolar lavage fluid less than 72 h after intubation and used Fourier Transform Infrared Spectroscopy to measure levels of dipalmitoylphosphatidylcholine (DPPC). A total of eleven COVID-19 patients with moderate-to-severe ARDS (CARDS) and 15 healthy controls were included. CARDS patients had lower DPPC levels than healthy controls. Moreover, a principal component analysis was able to separate patient groups into distinguishable subgroups. Our findings indicate markedly impaired pulmonary surfactant levels in COVID-19 patients, justifying further studies and clinical trials of exogenous surfactant.
© 2022. The Author(s).
Conflict of interest statement
DPCC analysis was part of a public–private partnership between the Department of Paediatrics, Holbaek Hospital, Region Zealand, Denmark and SIME Diagnostics Ltd. HV, NS, PV and PS reported being consultants and shareholders of SIME Diagnostics Ltd. TB reports personal fees and nonfinancial support from Bristol-Myers Squibb and Gilead. The rest of the authors have no conflicts of interest.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
